|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 22:03
|
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress (Business Wire)
|
|
|
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026
KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date
Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026
Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2025.
“In 2025, we strengthened Rocket's leadership in cardiovascular gene therapy, supported by more than five years of clinical experience in Danon disease and continued advancement across our PKP2-ACM and BAG3-DCM programs,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
